HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Cyclosporine | NeOral | 25mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 1995 | In Use | |||
Revumenib | Revuforj | 25mg, 110mg, 160mg | Chemotherapy | Enzyme Inhibitor | KMT2A | Yes | 2024 | In Use | ||||
NA | Cyclosporine | Gengraf | 25mg, 50mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 2010 | In Use | |||
NA | Cyclosporine | Sandimmune | 25mg, 50mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 1983 | In Use | |||
NA | Cysteamine Bitartrate | Procysbi | 25mg, 75mg, 300mg | Chemotherapy | Cystine-Depleting Agent | Yes | 2013 | In Use | ||||
NA | Umbralisib | Ukoniq | 260.2mg | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Yes | 2021 | In Use | |||
J9349 | Tafasitamab-cxix | MONJUVI | 2mg | Immunotherapy | Monoclonal Antibody | CD19 | No | 2020 | Apr 1, 2021 | In Use | ||
J9061 | Amivantamab | Rybrevant | 2mg | Immunotherapy | Monoclonal Antibody | EGFR, MET | No | 2021 | Jan 26, 2022 | In Use | ||
C9302 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Mar 26, 2025 | In Use | ||
C9070 | Tafasitamab-cxix | Monjuvi | 2mg | Immunotherapy | Monoclonal Antibody | CD19 | 2020 | Jan 1, 2021 | Apr 1, 2021 | No Longer Used | ||
NA | ixazomib | Ninlaro | 3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
NA | Pomalidomide | Pomalyst | 3 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2013 | In Use | |||
J9213 | Interferon Alfa-2a | Roeferon- A | 3 million units | Immunotherapy | Cytokine | Interferon | No | 2002 | Jan 1, 2009 | In Use | ||
J9216 | Interferon Gamma-1b | Actimmune | 3 million units | Immunotherapy | Cytokine | Interferon | No | 1999 | Jan 1, 2009 | In Use | ||
S0115 | Bortezomib | Velcade | 3.5 mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2003 | Jan 1, 2004 | Dec 31, 2004 | No Longer Used | |
NA | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | No | 2015 | In Use | |||
J9202 | Goserelin Acetate | Zoladex | 3.6 mg | Hormonal Therapy | GnRH Agonist | No | 1989 | Jan 1, 1997 | In Use | |||
J1950 | Leuprolide Acetate | Eligard, Lupron Depot, Viadur, Lupron | 3.75 mg | Hormonal Therapy | GnRH Agonist | No | 1989 | Jan 1, 1997 | In Use | |||
J3315 | Triptorelin Pamoate | Trelstar, Trelstar Mixject | 3.75 mg | Hormonal Therapy | GnRH Agonist | No | 2000 | Jan 1, 2003 | In Use | |||
C9431 | Paclitaxel | Taxol | 30 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
NA | Brigatinib | Alunbrig | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2017 | In Use | |||
S0087 | Alemtuzumab | Campath | 30 mg | Immunotherapy | Monoclonal Antibody | CD52 | No | 2001 | 2012 | Jan 1, 2002 | Dec 31, 2002 | No Longer Used |
J9265 | Paclitaxel | Taxol | 30 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 1994 | Dec 31, 2014 | No Longer Used | |
NA | Afatinib | Gliotrif | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use | |||
J1440 | Filgrastim | Neupogen, Zarxio | 300 mcg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 1991 | Jan 1, 2014 | Dec 31, 2013 | No Longer Used |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.